Amphastar Pharmaceuticals Inc. (AMPH)
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024. Third quarter Highlights Net revenues of $191.2 million for the third quarter GAAP net income of $40.4 million, or $0.78 per share, for the third quarter Adjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®, which has become a cornerstone in our portfolio, and Primatene MIST®, which is trending toward our goal of $100 million in sales per year.
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amphastar Pharmaceuticals Inc (AMPH) Trading Down 3.54% on Oct 2
Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previous close of $48.35.
Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects
Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies, dependency on Lilly for BAQSIMI manufacturing, and the impact of reference brand demand on generic products.
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at Click Here
6 Beaten Down Stocks Rated Buy (SA Quant)
The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations.
